DexCom, a Nasdaq-listed supplier of continuous glucose monitoring for people with diabetes, has set up its corporate venturing unit under Steve Pacelli.
Dexcom Ventures will invest in glucose sensing technology and adjacent areas, such as data analytics, remote patient monitoring and population health.
Pacelli said: “We strive to be value-add strategic investors by leveraging access to Dexcom’s unique industry expertise and technology leadership.
“While we have matured as a company over the years, we still consider ourselves to be a ‘start-up’ of sorts. We feel well positioned to invest early and support our portfolio companies as they pioneer markets.”
Kevin Sayer, chairman, president and CEO of Dexcom, added: “By establishing Dexcom Ventures, we believe we can advance innovative technologies that enable better health outcomes and complement our growth opportunity.”
